Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth

Cancer

Volumn 118, Issue 3, 2012, Pages 750-760

  Moriceau, Gatien ^a,b   Roelofs, Anke J ^c   Brion, Régis ^a,b,d   Redini, Franãoise ^a,b   Ebetion, Frank H ^e   Rogers, Michael J ^c   Heymann, Dominique ^a,b,d  

^a Department of Research   (France)

^b Universite de Nantes   (France)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d HÔTEL DIEU   (France)

^e Warner Chilcott Pharmaceuticals   (Ireland)

Author keywords

apomine; apoptosis; cell cycle; lovastatin; osteosarcoma

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID; MEVINOLIN; PHOSPHATE BUFFERED SALINE; PLACEBO; PROTEIN 1A; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE RAS; OSTEOSARCOMA; PRIORITY JOURNAL; PROTEIN PRENYLATION; PROTEIN TARGETING; SARCOMA CELL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DIPHOSPHONATES; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MICE; MICE, INBRED C3H; OSTEOSARCOMA; PROTEIN PRENYLATION; RATS; TUMOR CELLS, CULTURED;

EID: 84856211873     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26336     Document Type: Article

References (42)

1. Hogendoorn PC, ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21: v204-v213.
2. Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC,. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976; 37: 1-11.
3. Mori K, Ando K, Heymann D,. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Exp Rev Anticancer Ther. 2008; 8: 151-154.
4. Ando K, Mori K, Corradini N, Redini F, Heymann D,. Mifamurtide for the treatment of non-metastatic osteosarcoma. Exp Opin Pharmacother. 2011; 12: 285-292.
5. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ,. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev. 2004; 30: 609-641.
6. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK,. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Clin Invest. 1985; 76: 1748-1754.
7. Sebti SM, Tkalcevic GT, Jani JP,. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun. 1991; 3: 141-147.
8. Sinensky M, Beck LA, Leonard S, Evans R,. Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis. J Biol Chem. 1990; 265: 19937-19941.
9. Sleijfer S, van der Gaast A, Planting AS, Stoter G, Verweij J,. The potential of statins as part of anti-cancer treatment. Eur J Cancer. 2005; 41: 516-522.
10. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996; 2: 483-491.
11. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res. 2001; 7: 158-167.
12. Istvan ES, Deisenhofer J,. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001; 292: 1160-1164.
13. Nakanishi M, Goldstein JL, Brown MS,. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem. 1988; 263: 8929-8937.
14. Jackson B, Gee AN, Guyon-Gellin Y, et al. Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4- hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i). Arzneimittelforschung. 2000; 50: 380-386.
15. Roitelman J, Masson D, Avner R, et al. Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3- methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity. J Biol Chem. 2004; 279: 6465-6473.
16. Flach J, Antoni I, Villemin P, Bentzen CL, Niesor EJ,. The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. Biochem Biophys Res Commun. 2000; 270: 240-246.
17. Niesor EJ, Flach J, Lopes-Antoni I, Perez A, Bentzen CL,. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharml Des. 2001; 7: 231-259.
18. Roelofs AJ, Edwards CM, Russell RGG, Ebetino FH, Rogers MJ, Hulley PA,. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther. 2007; 322: 228-235.
19. Correll CC, Ng L, Edwards PA,. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem. 1994; 269: 17390-17393.
20. Alberts DS, Hallum AV, Stratton-Custis M, et al. Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of apomine (SR-45023A), a novel oral biphosphonate anticancer drug. Clin Cancer Res. 2001; 79: 1246-1250.
21. Edwards CM, Mueller G, Roelofs AJ, et al. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo. Int J Cancer. 2007; 120: 1657-1663.
22. Voziyan PA, Goldner CM, Melnykovych G,. Farnesol inhibits phosphatidylcholine biosynthesis in cultured cells by decreasing choline phosphotransferase activity. Biochem J. 1993; 295: 757-762.
23. Miquel K, Pradines A, Terce F, Selmi S, Favre G,. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem. 1998; 273: 26179-26186.
24. Anthony ML, Zhao M, Brindle KM,. Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J Biol Chem. 1999; 274: 19686-19692.
25. Bonate PL, Floret S, Bentzen C,. Population pharmacokinetics of apomine: a meta-analysis in cancer patients and healthy male. Br J Clin Phamarcol. 2004; 58: 142-155.
26. Klein B, Pals S, Masse R, et al. Studies of bone and soft-tissue tumours induced in rats with radioactive cerium chloride. Int J Cancer. 1977; 20: 112-119.
27. Thiery J, Perdereau B, Gongora R, Gongora C, Mazabraud A,. Un modele experimental d'osteosarcome chez le rat. Sem Hop Paris. 1982; 58: 1686-1689.
28. Kamijo A, Koshino T, Uesugi M, Nitto H, Saito T,. Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett. 2002; 188: 213-219.
29. Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010; 70: 10329-10339.
30. Kruh GD,. Introduction to resistance to anticancer agents. Oncogene. 2003; 22: 7262-7264.
31. Perez P, Rincon SA,. Rho GTPases: regulation of cell polarity and growth in yeasts. Biochem J. 2010; 426: 243-253.
32. Clendening JW, Pandyra A, Boutros PC, et al. Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci. 2010; 107: 15051-15056.
33. Laezza C, Fiorentino L, Pisanti S, et al. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J Mol Med. 2008; 86: 1341-1351.
34. Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010; 119: 137-144.
35. Guruswamy S, Rao CV,. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: implications for colon cancer prevention. Int J Oncol. 2009; 35: 1037-1043.
36. Park IH, Kim JY, Jung JI, Han J,. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs. 2010; 28: 791-799.
37. Wei N, Mi MT, Zhou Y,. Influences of lovastatin on membrane ion flow and intracellular signaling in breast cancer cells. Cell Mol Biol Lett. 2006; 12: 1-15.
38. Khaidakov M, Wang W, Khan JA, Kang B, Hermonat PL, Mehta JL,. Statins and angiogenesis: is it about connections? Biochem Biophys Res Commun. 2009; 387: 543-547.
39. Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ,. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol. 2008; 111: 102-105.
40. Lubet RA, Boring D, Steele VE, Ruppert JM, Juliana MM, Grubbs CJ,. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis. Cancer Prevent Res. 2009; 2: 161-167.
41. Wang C, Shui H, Chang T,. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer. 2010; 126: 578-582.
42. Rodrigues AC,. Efflux and uptake transporters as determinants of statin response. Exp Opin Drug Metab Toxicol. 2010; 6: 621-632.